The oral microbiome: 700 species in careful balance
The human oral cavity is one of the most microbially diverse environments in the body. The Human Oral Microbiome Database (HOMD) catalogues over 700 bacterial species across 13 phyla, representing a complex ecosystem that colonises distinct niches — the tooth surface, the gingival sulcus (the space between tooth and gum), the dorsal tongue, buccal mucosa, hard and soft palate, and saliva. Each niche selects for distinct microbial communities based on oxygen availability, pH, substrate availability, and epithelial surface properties.
In health, the oral microbiome is dominated by health-associated species including Streptococcus salivarius, Streptococcus mitis, Veillonella species (obligate anaerobes that consume lactate), Neisseria, Haemophilus, and Rothia. These communities maintain homeostasis partly by competitive exclusion of pathogenic species, by consuming acid produced by other bacteria, and by producing antimicrobial peptides and bacteriocins that suppress pathogen outgrowth. The concept of a “healthy oral microbiome” is not simply the absence of pathogens but the presence of these active ecological competitors.
Two oral diseases account for the vast majority of the global burden of oral ill-health. Dental caries (cavities) is driven by acidogenic and aciduric bacteria — primarily Streptococcus mutans — that ferment dietary sugars to lactic acid, reducing pH below the critical threshold at which hydroxyapatite demineralises. Periodontal disease (gum disease) is a polymicrobial infection of the supporting structures of the teeth, characterised by an anaerobic dysbiotic community in the gingival sulcus and subgingival plaque. These are distinct microbiological problems requiring different approaches.
Streptococcus mutans: acid, biofilm, and the pH battlefield
Streptococcus mutans is the primary cariogenic pathogen. Its pathogenicity depends on three related properties. First, it is highly efficient at fermenting sucrose to lactic acid — it carries multiple phosphotransferase system transporters for sugar uptake and a high-activity lactate dehydrogenase. Second, it is aciduric: it can maintain growth at pHs down to approximately 4.5, far lower than most oral streptococci can tolerate, giving it a competitive advantage as the pH drops. Third, it produces extracellular polysaccharides from sucrose — specifically glucans synthesised by glucosyltransferases (GtfB, GtfC, GtfD) — that mediate biofilm formation on tooth surfaces. This biofilm (dental plaque) provides a protected matrix within which local pH can drop severely following sugar exposure.
The low-pH environment that S. mutans creates is relevant to spirulina in a straightforward way. Spirulina powder dissolved in water or saliva raises pH — it is alkaline (pH approximately 8–10 in aqueous solution), owing to its bicarbonate content and amino acid composition. Buffering the oral environment toward alkalinity after sugar exposure is theoretically protective against S. mutans’ competitive acid advantage. Whether this buffering effect is large enough or sustained enough to be clinically meaningful from dietary spirulina consumption is unproven, but the chemistry is sound.
Porphyromonas gingivalis: the keystone oral pathogen
Porphyromonas gingivalis occupies a remarkable ecological niche in the subgingival microbiome. Despite being present in very low abundance in even severe periodontitis cases (often less than 1% of total subgingival bacteria), it exerts a disproportionate effect on community structure and disease progression — earning the designation “keystone pathogen” from the group of George Hajishengallis at the University of Pennsylvania in a widely cited 2012 paper in Nature Reviews Microbiology. A pathogen can have keystone status at low abundance if it manipulates the community environment rather than simply outcompeting other species numerically.
P. gingivalis achieves its dysbiotic influence through several mechanisms. Its primary virulence factors are gingipains — a family of cysteine proteases. The two classes are arginine-specific gingipains (Rgp, including RgpA and RgpB) and lysine-specific gingipain (Kgp). These proteases are extraordinarily broad-spectrum: they degrade host proteins including complement components (C3, C5), immunoglobulins, cytokines, and extracellular matrix proteins. Critically, gingipains degrade complement C5 to generate the anaphylatoxin C5a, which signals through C5a receptor 1 on macrophages and neutrophils to disable their phagocytic killing activity through cross-talk with TLR2 signalling. This complement hijacking is the specific mechanism by which P. gingivalis at very low abundance can suppress effective neutrophil and macrophage killing — not just of itself but of all bacteria in the subgingival pocket — enabling dysbiosis to emerge.
The systemic associations of P. gingivalis have attracted enormous research interest beyond dentistry. Its presence or antibody titres to it have been associated epidemiologically with cardiovascular disease (gingipains damage vascular endothelium, P. gingivalis has been found in atherosclerotic plaques), rheumatoid arthritis (P. gingivalis-produced peptidylarginine deiminase can citrullinate host proteins, generating neoantigens relevant to anti-citrullinated protein antibody-positive RA), and Alzheimer’s disease (gingipains have been identified in Alzheimer’s brain tissue in a widely discussed but still contested 2019 Science Advances paper by Dominy and colleagues). The causal direction of these associations is debated, but the biological plausibility of P. gingivalis contributing to systemic disease through inflammatory and protease mechanisms is well-established.
Phycocyanin’s direct antimicrobial activity
Several in vitro studies have tested spirulina-derived phycocyanin and crude spirulina extracts against oral pathogens. The evidence for direct antimicrobial activity is predominantly in vitro at this stage, but the findings are specific enough to be informative.
Against P. gingivalis, phycocyanin has shown inhibitory activity in agar diffusion and broth microdilution assays. The proposed mechanism involves phycocyanin’s photosensitiser properties: phycocyanobilin can absorb light at 620 nm and transfer energy to molecular oxygen to generate singlet oxygen and superoxide, making it an effective photodynamic antimicrobial agent (PDAM). Photodynamic therapy using phycocyanin-based sensitisers has been investigated as a method to reduce subgingival pathogen load through light activation in the gingival sulcus. This is methodologically distinct from dietary intake, but the photochemical mechanism is documented.
Against S. mutans, the antimicrobial data are less consistent. Some studies find minimum inhibitory concentrations (MICs) for spirulina extracts against S. mutans in ranges that could be physiologically achievable in the oral cavity; others find little activity. The variability likely reflects differences in extract preparation, the relative contributions of phycocyanin versus other spirulina components (fatty acids, polysaccharides), and growth conditions in the assays. In biofilm models — more clinically relevant than planktonic MIC assays — spirulina extracts have shown ability to reduce S. mutans biofilm formation, possibly by interfering with glucosyltransferase activity or by disrupting biofilm-matrix polysaccharides.
Chlorophyllin as an oral antimicrobial
Spirulina contains significant amounts of chlorophyll — approximately 1–1.5% of dry weight. Chlorophyllin, the water-soluble sodium-copper derivative of chlorophyll produced during processing, has a distinct antimicrobial profile from phycocyanin. Chlorophyllin has documented antimicrobial activity against a range of bacteria, and its activity in the oral cavity has been specifically examined because it is one of the active ingredients in certain mouthwashes.
The mechanism of chlorophyllin’s antimicrobial activity involves disruption of bacterial membrane integrity and, like phycocyanobilin, photosensitisation under visible light. Chlorophyllin absorbs strongly in the red (665 nm) and blue (430 nm) portions of the visible spectrum, generating reactive oxygen species upon illumination that damage bacterial membranes and DNA. Unlike antibiotic-class antimicrobials, the mechanism of photodynamic killing makes resistance development less likely, because the killing pathway is through non-specific oxidative damage rather than inhibition of a specific enzymatic target.
The relevance of chlorophyllin specifically in spirulina consumed as a dietary supplement rather than applied topically is uncertain. Most of the chlorophyllin in swallowed spirulina would pass into the stomach and intestine rather than remaining in contact with oral surfaces for extended periods. The route of application matters enormously for antimicrobial efficacy: a compound needs sustained contact with the target bacteria to inhibit them. Spirulina supplements swallowed in capsule form have essentially no oral contact time; spirulina consumed as a powder dissolved in liquid or incorporated into foods that are held in the mouth longer would have greater theoretical oral bioavailability.
Vitamin K2 and dental health: a less-discussed spirulina angle
During cultivation and processing, certain bacteria associated with spirulina production — including contaminating bacteria in open-pond systems or symbiotic bacteria — can produce menaquinone (vitamin K2, specifically MK-4 and MK-7 forms). The relationship between vitamin K2 and dental health has attracted interest because K2-dependent carboxylation of osteocalcin and MGP (matrix Gla protein) contributes to mineralisation of dentine and enamel. Epidemiological data from traditional populations consuming fermented foods with high K2 content have been cited in discussions of caries resistance.
The vitamin K2 content of commercial spirulina products is generally low and variable — it is not a reliable source compared to fermented foods like natto (which contains extremely high levels of MK-7) or hard cheeses. This angle is therefore of limited practical significance for most spirulina supplements, though it is worth noting as part of the nutritional profile.
Clinical studies: what exists
A small number of clinical studies have examined spirulina-containing oral care formulations. A randomised controlled trial published in Journal of Clinical and Diagnostic Research in 2016 examined a spirulina mouthwash against chlorhexidine (the gold standard antimicrobial mouthwash) for plaque control and gingival health. The spirulina mouthwash showed comparable plaque inhibition and gingival inflammation reduction to chlorhexidine over a 21-day trial period in a small group of adults. This is an encouraging finding, but a trial of this size (typically 20–60 participants in such studies) is insufficient to establish clinical equivalence, and the follow-up period is very short.
Another study examined a spirulina-containing toothpaste against a standard fluoride toothpaste for effects on gingival bleeding and plaque index over 3 months. Modest benefits in the spirulina group were reported. The study methodology in available publications is variable in quality, and most are single-site trials with limited blinding.
The honest summary of the clinical evidence is: promising in vitro data, biologically plausible mechanisms, and a handful of small clinical studies in oral formulations that suggest possible benefit. The evidence does not yet support strong clinical recommendations. What the field needs is larger, better-blinded trials of spirulina as a dietary supplement (rather than just topical formulation) with validated microbiome endpoints measuring actual P. gingivalis or S. mutans burden in plaque, not just proxy measures like plaque index and bleeding scores.